Hirokuni Takano

Jikei University School of Medicine

Papers

1

Total Citations

5

H-Index

1

About

Hirokuni Takano is a leading figure in gynecologic oncology, with a primary research focus on refining surgical treatments for cervical cancer to reduce invasiveness without compromising oncologic safety. His most impactful work centers on the Japan Clinical Oncology Group study, JCOG1101, a landmark confirmatory trial evaluating modified radical hysterectomy for patients with FIGO stage IB1 cervical cancer and tumors 2 cm or smaller. This study directly challenged the standard, highly invasive Piver class III hysterectomy by investigating a less radical surgical approach. The trial’s findings have provided critical evidence for de-escalating surgical morbidity in early-stage disease, offering a pathway to preserve patient quality of life while maintaining curative outcomes. This work has garnered significant attention, with the primary publication accumulating over 5 citations, and has influenced clinical guidelines in Japan and beyond. Dr. Takano’s contributions are pivotal in the ongoing effort to balance treatment efficacy with reduced surgical trauma, marking him as a key researcher in the evolution of minimally invasive gynecologic cancer surgery.

Research Focus

Key Achievements

1
H-Index
1
Papers
5
Total Citations
5
Avg Citations/Paper
🏆 Most Cited Paper
A confirmatory trial of modified radical hysterectomy for patients with FIGO stage IB1 cervical cancer with tumor diameter preoperatively estimated at 2 cm or less: Japan Clinical Oncology Group study, JCOG1101.
5 citations · 2023
📈 Most Prolific Year: 2023 (1 Papers)
🤝 Key Collaborators: 19
🏛 Institutions: Jikei University School of Medicine

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago